AQST News and Press, Aquestive Therapeutics Inc. From 05/11/21

WARREN, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the managemen...

Image source: The Motley Fool. Aquestive Therapeutics, Inc. (NASDAQ: AQST) Q1 2021 Earnings Call May 05, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Aquestive Therapeutics, Inc. (AQST) Q1 2021 Earnings Call Tran...

Aquestive Therapeutics, Inc. (AQST) Q1 2021 Earnings Conference Call May 05, 2021, 08:00 AM ET Company Participants Stephanie Carrington - IR Keith Kendall - President and CEO Ernie Toth - Interim CFO Daniel Barber - SVP and COO Conference Call Participants Gary Nachman - BMO Capital Markets ...

Aquestive Therapeutics (AQST): Q1 GAAP EPS of -$0.41 beats by $0.01.Revenue of $11.12M (+26.8% Y/Y) beats by $2.16M.Press Release For further details see: Aquestive Therapeutics EPS beats by $0.01, beats on revenue

On track to refile Libervant™ (diazepam) Buccal Film New Drug Application (NDA) by end of second quarter 2021 Initiated first-in-human Phase 1 pharmacokinetic (PK) study for AQST-109 epinephrine sublingual film candidate Sympazan ® (clobazam) continues to me...

WARREN, N.J., April 21, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it will rep...

On Thursday, 4/9/2021, KemPharm announced an updated commercialization agreement with its marketing partner, Corium. This was based on a post-approval commercial assessment conducted with GPC, Corium's parent. The agreement added increased royalty rates, and $130M in potential sales m...

Aquestive Therapeutics is a world leader in oral film drug delivery with its PharmFilm technology. The company has developed several approved products that offer several advantage over other delivery methods. Despite the ongoing pandemic, Aquestive was able to show a strong performanc...

Gainers: Greenlane (GNLN) +37%, SunLink Health Systems (SSY) +17%, Aquestive Therapeutics (AQST) +14%, Evolus (EOLS) +14%, Spectrum Pharmaceuticals (SPPI) +11%.Losers: 9 Meters Biopharma (NMTR) -22%, Delcath Systems (DCTH) -20%, Celsion (CLSN)...

Provides in-depth scientific and clinical data in R&D event today at 9:00 am ET Outlines data from two completed Phase 1 pharmacokinetic (PK) trials for AQST-108 (dipivefrin) sublingual film Articulates development strategy for second prodrug candidate, AQST-109 su...